ML
Therapeutic Areas
Personalis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NeXT Personal® | Molecular Residual Disease (MRD) Detection & Monitoring in Solid Tumors | Commercial |
| ImmunoID NeXT Platform® | Comprehensive Genomic Profiling for Therapy Selection & Biomarker Discovery | Commercial |
| Personalis ACE ImmunoID Assay | Tumor Mutational Burden (TMB) & Microsatellite Instability (MSI) Testing | Commercial |
| MRD Detection in Hematologic Malignancies | MRD for Leukemia, Lymphoma, Multiple Myeloma | Development |
| Early Cancer Detection | Multi-Cancer Early Detection (MCED) | Research |
Leadership Team at Personalis
JW
John West
Chief Executive Officer
AT
Aaron Tachibana
Chief Financial Officer & Chief Operating Officer
RC
Richard Chen
Chief Medical Officer & Executive Vice President of R&D
MS
Michael Snyder
Chairman of the Scientific Advisory Board & Co-founder
CX
Chunlin Xiao
Vice President, Biopharma Business Development
IL
Ivan Liachko
Vice President, Engineering & Computational Biology
SD
Scott D. Kahn
Chief Information Officer
GZ
Ginger Zhou
Vice President, Bioinformatics
JC
J. Christopher Miner
Board Member
LR
Liam Ratcliffe
Board Member